This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
The initiative is focused on a problem that continues to plague cancer outcomes in India
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
Patients with BRCA mutations often face aggressive disease and poor prognosis
Subscribe To Our Newsletter & Stay Updated
